Carlo Genova

Italian Oncology Group of Clinical Research — Italy

Medicine · Health Sciences

38h-index6.1kcitations310works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(138), Cancer Immunotherapy and Biomarkers(101), Lung Cancer Research Studies(52), Lung Cancer Diagnosis and Treatment(42), Cancer Genomics and Diagnostics(41)

Publications308 total

Braf-mutant metastatic non–small-cell lung cancer: Real world data from the Italian biomarker atlas database
European Journal of Cancer·2025Open Access
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry
The Oncologist·2025Open Access
Hunting for signal in the noise: identifying robust CT radiomic features across variable scanning settings
European Radiology·2025
Pericardial Mesothelioma: Diagnostic and Therapeutic Management, a Population-Based Study in Italy
Cancers·2025Open Access
Detection and Monitoring ALK Gene Alterations through Liquid Biopsy in Advanced NSCLC Treated with Alectinib: Preliminary TANGIBLE Study Results
The Journal of Liquid Biopsy·2025Open Access
Plasma and Pleural Effusion as reflective mirrors of the Immune Landscape in two histotypes of Pleural Mesothelioma
The Journal of Liquid Biopsy·2025Open Access
Platelet gene expression profiling as a liquid biopsy tool to monitor Immunotherapy resistance in advanced NSCLC patients
The Journal of Liquid Biopsy·2025Open Access
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
Lung Cancer·2025Open Access
Diagnostic and Therapeutic Management of Mesothelioma of the Tunica Vaginalis Testis: A Population-Based Study in Italy
Cancers·2025Open Access
Peritoneal mesothelioma and asbestos exposure: a population-based case–control study in Italy, 2000–2021
Occupational and Environmental Medicine·2025Open Access
P17.40.B EFFECTIVENESS OF TARGET THERAPY IN ADULT AND PEDIATRIC RECURRENT HIGH GRADE GLIOMA PATIENTS WITH BRAFV600E MUTATION OR NTRK FUSION: A REAL-LIFE MULTICENTRIC ITALIAN ANALYSIS.
Neuro-Oncology·2025Open Access
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Lung Cancer·2025Open Access
Influence of medical educational background on the diagnostic quality of <scp>ChatGPT</scp>‐4 responses in internal medicine: A pilot study
European Journal of Clinical Investigation·2025· 2 citedOpen Access
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses
ESMO Open·2025· 4 citedOpen Access
1775eP Real-world evaluation of liquid biopsy as a diagnostic tool across a regional thoracic oncology network: Insights from a 3-year HUB &amp; SPOKES model experience
Annals of Oncology·2025
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study
ESMO Open·2025· 4 citedOpen Access
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 &lt; 50%: results from an Italian observational study
Cancer Immunology Immunotherapy·2025· 2 citedOpen Access
Foodscape vegani. Un'indagine esplorativa sul rapporto fra luoghi, persone e cibo a Torino
RIVISTA GEOGRAFICA ITALIANA·2025
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors
Cell Reports·2025· 1 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

Francesco Grossi(31), Maria Giovanna Dal Bello(25), Simona Coco(19), Erika Rijavec(18), Angela Alama(16), Giovanni Rossi(13), Federica Biello(12), Rita Chiari(11), Giulia Barletta(11), Alessio Cortellini(10), Alessandro De Toma(9), Raffaele Giusti(9), Irene Vanni(9), Marco Tagliamento(9), Marcello Tiseo(8), Biagio Ricciuti(8), Marco Filetti(8), Diego Cortinovis(8), Diego Signorelli(8), Danilo Rocco(8)